CRIS

Permanent URI for this communityhttps://investigadores.udd.cl/handle/123456789/1

Browse

Settings

Subject: search.filters.subject.vaccination

Search Results

Now showing 1 - 10 of 49
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Tackling cutaneous herpes simplex virus disease with topical immunomodulators—a call to action
    (American Society for Microbiology, 2025-03-13)
    DUARTE PEÑALOZA, LUISA FERNANDA  
    ;
    Javier Carbone-Schellman
    ;
    Susan M. Bueno
    ;
    Alexis M. Kalergis
    ;
    Claudia A. Riedel
    Antivirals play important roles in restricting viral diseases. Nevertheless, they act on a relatively limited number of viruses and occasionally display partial effectiveness in some tissues or against escape variants. Although vaccination remains the most cost-effective approach for preventing microbial diseases, developing prophylactic or therapeutic solutions for pathogens, such as herpes simplex viruses (HSVs), that effectively reduce their clinical manifestations in the skin has proven exceptionally challenging despite extensive research. Alternatively, a less explored approach for tackling HSV skin infection involves using topical immunomodulatory molecules to potentiate the host’s innate antiviral immune responses. When applied directly to herpetic skin lesions where viral antigen is present, this strategy has the potential to elicit virus-specific adaptive immunity. Based on currently available data, we foresee substantial potential for this approach in addressing HSV skin infections, along with additional prospects to advance understanding of skin biology and apply relevant new findings to other dermatological conditions. However, due to the limited number of case studies evaluating this method and its safety profile, particularly in immunocompromised individuals and pregnant women, further research is crucial, especially to assess the effects of immunomodulators in these vulnerable populations. Here, we revisit and discuss the use of immunomodulatory molecules for potentiating the host immune response against HSV skin infection and call for action for increased research and clinical trials regarding the possible benefits of this latter strategy for treating HSV cutaneous disease and recurrences. We also revisit and discuss antivirals and vaccine candidates against HSVs.
    Scopus© Citations 2  7
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
      10
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Infectious diseases prevention and vaccination in migrants in Latin America: The challenges of transit through the treacherous Darien gap, Panama
    (Elsevier BV, 2025-05)
    Alfonso J. Rodriguez-Morales
    ;
    María Camila Puerta-Arias
    ;
    Rola Husni
    ;
    Juan J. Montenegro-Idrogo
    ;
    Juan Pablo Escalera-Antezana
    Scopus© Citations 12  1
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Cancer plans should consider local needs
    (Elsevier BV, 2025-02)
    Bettina Müller
    ;
    Raul Murillo
      1Scopus© Citations 2
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    SARS-CoV-2 Infection Risk by Vaccine Doses and Prior Infections Over 24 Months: ProHEpiC-19 Longitudinal Study
    (JMIR Publications Inc., 2024-11-22)
    Pere Torán-Monserrat
    ;
    Noemí Lamonja-Vicente
    ;
    Anna Costa-Garrido
    ;
    Lucía A Carrasco-Ribelles
    ;
    Bibiana Quirant
    <jats:title>Abstract</jats:title> <jats:sec sec-type="background"> <jats:title>Background</jats:title> <jats:p>As the vaccination campaign against COVID-19 progresses, it becomes crucial to comprehend the lasting effects of vaccination on safeguarding against new infections or reinfections.</jats:p> </jats:sec> <jats:sec sec-type="objective"> <jats:title>Objective</jats:title> <jats:p>This study aimed to assess the risk of new SARS-CoV-2 infections based on the number of vaccine doses, prior infections, and other clinical characteristics.</jats:p> </jats:sec> <jats:sec sec-type="methods"> <jats:title>Methods</jats:title> <jats:p>We defined a cohort of 800 health care workers in a 24-month study (March 2020 to December 2022) in northern Barcelona to determine new infections by SARS-CoV-2. We used extended Cox models, specifically Andersen-Gill (AG) and Prentice-Williams-Peterson, and we examined the risk of new infections. The AG model incorporated variables such as sex, age, job title, number of chronic conditions, vaccine doses, and prior infections. Additionally, 2 Prentice-Williams-Peterson models were adjusted, one for those individuals with no or 1 infection and another for those with 2 or 3 infections, both with the same covariates as the AG model.</jats:p> </jats:sec> <jats:sec sec-type="results"> <jats:title>Results</jats:title> <jats:p>The 800 participants (n=605, 75.6% women) received 1, 2, 3, and 4 doses of the vaccine. Compared to those who were unvaccinated, the number of vaccine doses significantly reduced (<jats:italic>P</jats:italic>&lt;.001) the risk of infection by 66%, 81%, 89%, and 99%, respectively. Unit increase in the number of prior infections reduced the risk of infection by 75% (<jats:italic>P</jats:italic>&lt;.001). When separating individuals by number of previous infections, risk was significantly reduced for those with no or 1 infection by 61% (<jats:italic>P</jats:italic>=.02), and by 88%, 93%, and 99% (<jats:italic>P</jats:italic>&lt;.001) with 1, 2, 3, or 4 doses, respectively. In contrast, for those with 2 or 3 previous infections, the reduction was only significant with the fourth dose, at 98% (<jats:italic>P</jats:italic>&lt;.001). The number of chronic diseases only increased the risk by 28%‐31% (<jats:italic>P</jats:italic>&lt;.001) for individuals with 0‐1 previous infections.</jats:p> </jats:sec> <jats:sec sec-type="conclusions"> <jats:title>Conclusions</jats:title> <jats:p>The study suggests that both prior infections and vaccination status significantly contribute to SARS-CoV-2 immunity, supporting vaccine effectiveness in reducing risk of reinfection for up to 24 months after follow-up from the onset of the pandemic. These insights contribute to our understanding of long-term immunity dynamics and inform strategies for mitigating the impact of COVID-19.</jats:p> </jats:sec>
    Scopus© Citations 1  2
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Reiseimpfungen
    (Georg Thieme Verlag KG, 2024-11)
    Camilla Rothe
    ;
    Deike Rosenbusch
    ;
    Silja Bühler
    ;
    Gerd Burchard
    ;
    Torsten Feldt
      1
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Scopus© Citations 1  2
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Prevención de la infección por virus respiratorio sincicial en lactantes. ¿Qué se ha hecho y en qué estamos hoy?
    (2023)
    Jose M. Novoa Pizarro
    ;
    Birte Christina Lindemann Tappert
    ;
    Vivian R. Luchsinger Farias
    ;
    Sergio L. Vargas Munita
    La infección por virus respiratorio sincicial (VRS) es causa frecuente de morbimortalidad en niños. Recientemente se han logrado grandes avances en el desarrollo de nuevos anticuerpos monoclonales y vacunas gracias al reconocimiento de la conformación estructural de proteínas del virus. El objetivo de este estudio es revisar los avances relacionados con la prevención de VRS en los primeros 6 meses de vida. Avances en biología estructural han demostrado que la proteína de fusión del VRS (Proteína F) en su conformación prefusión (Pre-F) constituye un excelente antígeno para desarrollar anticuerpos monoclonales y vacunas para prevenir infecciones por virus respiratorio sincicial (VRS). Un nuevo anticuerpo monoclonal de dosis única, nirsevimab, tiene mayor poder neutralizante que palivizumab actualmente disponible, y una protección prolongada por 5-6 meses. Nirsevimab tiene eficacia demostrada de 76,8 % (IC 95%: 49,4-89,4) para prevenir infección respiratoria baja a 150 días después de la inyección, disminuyendo el riesgo de hospitalizarse en UCI en un 90,1% (IC 95%: 16,4- 98,8). Clesrovimab es otro anticuerpo monoclonal, de dosis única, que también ha presentado promisorios resultados en los ensayos fase 1b-2a. Mas recientemente se ha desarrollado, replicando con ingeniería genética, la proteína F estabilizada en su estado Pre-F como antígeno, una vacuna bivalente contra VRS A y B (Bivalent Prefusion F) la que, administrada a embarazadas, entre las 24-36 semanas de gestación, induce altos niveles de anticuerpos maternos con elevado traspaso transplacentario al feto. Esta vacuna ha demostrado una eficacia de 81,8% (IC 95%: 40,6-96,3) a 90 días y de 69,4% (IC 95%: 44,3-84,1) a 180 días para prevenir enfermedad grave por VRS sin eventos de seguridad detectados hasta el momento. Estos desarrollos confieren protección efectiva mediante inmunidad pasiva contra VRS que dura los primeros 5-6 meses de vida, y tanto en el caso de nirsevimab como la vacuna PreF para embarazadas ya ha sido aprobado para su uso en Europa por EMA, Canadá y en Estados Unidos por la FDA.
      13Scopus© Citations 2
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
      2
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Navigating economic turmoil: Chilean businesses during COVID-19 lockdowns and vaccine rollouts
    (2023)
    Julio A. Pertuze
    ;
    José Pablo Montégu
    ;
    Cecilia González
    ;
    Rafael Araos  
    ;
    Paula Daza
    Scopus© Citations 1